About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Investor Centre
- Investor Centre
- News & ASX Announcements
Contact

Hit enter to search or ESC to close

Phosphagenics and Mylan Agree Settlement

December 19, 2018

Click here to read more

Post navigation

Voluntary Withdrawal from OTCQX

2019 Annual General Meeting Results

Related Posts

Phosphagenics Signs Development Agreement with tesa Labtec for TPM/Oxymorphone Patch

October 22, 2015

Terumo Shifts Focus from Oxymorphone Patch to Injectables

March 20, 2018

Mylan Arbitration Update – expert report on quantum of damages claimed filed

May 29, 2017

Recent Posts

Ashland Purchases Manufacturing Rights for VitalET and TPM
June 20, 2019
Change of Company Name and ASX Code
May 24, 2019
2019 Annual General Meeting Results
May 22, 2019

Categories

Analyst Coverage
Company Announcement
Company Report
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- News & ASX Announcements

© Copyright 2019 Avecho Biotechnology Ltd.